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Abstract
Neostigmine and sugammadex are two medications used to reverse the neuromuscular blockade
caused by nondepolarizing aminosteroidal neuromuscular blocking agents. Research has shown
an association between the use of acetylcholinesterase inhibitors, such as neostigmine, and
residual neuromuscular blockade in pediatric patients. Sugammadex has been shown to reduce
residual neuromuscular blockade in adults without adverse effects, but minimal research has
been performed on the effects of sugammadex in the pediatric population. Therefore, the
objective of the present study is to compare sugammadex and neostigmine to determine if using
sugammadex instead of neostigmine reduces postoperative adverse effects in the pediatric
population. A systematic, computerized search was conducted on PubMed, MEDLINE,
EMBASE, and the Cochrane Library, as well as the clinical trials registries: www.controlledtrials.com and clinicaltrials.gov. Studies comparing sugammadex versus neostigmine in the
pediatric population receiving nondepolarizing neuromuscular blocking agents were included.
The present study shows that sugammadex rapidly and efficiently reverses neuromuscular
blockade in the pediatric population with less adverse effects than neostigmine. Furthermore, it
has been found to be as safe and effective in the pediatric population as in the adult population.
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Sugammadex versus Neostigmine in Reducing Postoperative Adverse
Effects in the Pediatric Population
In order to better understand the current anesthesia practices and implications for use of
sugammadex versus neostigmine among pediatric patients, it is important to comprehend the
function of neuromuscular blocking agents, neuromuscular blockade, and the function of reversal
agents. Neuromuscular blocking agents, or paralytics, are routinely administered by anesthesia
providers in the operating room. Many pediatric patients receive rocuronium or vecuronium for
surgery due to fewer adverse effects. Rocuronium and vecuronium are nondepolarizing
neuromuscular blocking agents and act by competitively blocking the binding of acetylcholine at
the neuromuscular junction in skeletal muscle. The two agents most often used to reverse
nondepolarizing neuromuscular blocking agents are sugammadex and neostigmine.
Sugammadex is a selective relaxant binding agent with a novel approach to reversing
nondepolarizing aminosteroidal neuromuscular blocking agents. It noncompetitively binds
rocuronium and vecuronium, which separates them from nicotinic receptors at the neuromuscular
junction, resulting in the reversal of the neuromuscular blockade. Before sugammadex,
acetylcholinesterase inhibitors, such as neostigmine, were the only reversal agents available.
These medications work by inhibiting the breakdown of acetylcholine. However,
acetylcholinesterase inhibitors are associated with bradycardia, bronchospasm, and other
muscarinic side effects. To counter these effects, anticholinergic drugs, such as glycopyrrolate,
are administered with acetylcholinesterase inhibitors. However, anticholinergics can produce
their own undesirable side effects, such as tachycardia and confusion.
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Research has shown an association between the use of acetylcholinesterase inhibitors and
residual neuromuscular blockade in pediatric patients. Postoperative residual neuromuscular
blockade increases the risk of respiratory complications, such as pulmonary atelectasis, airway
obstruction, and decreased oxygen saturation in all populations. Young pediatric patients could
be at further risk for respiratory complications due to immature respiratory musculature,
diminished functional residual capacity, and reduced surface area for gas exchange.
Several studies have been performed that show the efficacy of sugammadex in reversing
neuromuscular blockade in the adult population without adverse effects, but minimal research
has been performed on the effects of sugammadex in the pediatric population. Therefore, the
purpose of the current study is to provide a comprehensive review of the different implications of
the use of sugammadex and neostigmine, and to provide a better understanding of how the use of
sugammadex can reduce postoperative adverse effects in the pediatric population.
Methodology
A systematic, computerized search was conducted on PubMed, MEDLINE, EMBASE,
and the Cochrane Library, as well as the clinical trials registries: www.controlled-trials.com and
clinicaltrials.gov. The search was run on October 27, 2019, November 3, 2019, and November 9,
2019. Date restrictions were placed, limiting the studies to within six years of the date of the
search, with no language restrictions applied. The search components “sugammadex”,
“neostigmine”, and “pediatric” were used. Studies comparing sugammadex versus neostigmine
in the pediatric population receiving nondepolarizing neuromuscular blocking agents were
included. The reference lists of the included studies were searched, and relevant studies were
included. The studies include male and female pediatric patients less than 18 years of age with a
physical status classification of I to IV who had received nondepolarizing neuromuscular
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blocking agents and sugammadex or neostigmine. Patients and/or guardians consented to be
included in the individual studies.
Literature Review
Neuromuscular blocking agents are routinely administered during induction by anesthesia
providers in the operating room. Not only do they facilitate intubation and mechanical ventilation,
but they also improve surgical conditions for the surgeon due to the reduction of muscle tone
(Bruintjes et al., 2017; Martini et al., 2014). The reversal of neuromuscular blockade during
emergence is an essential aspect of anesthesia and involves neuromuscular monitoring.
Incomplete reversal of neuromuscular blockade can result in postoperative pulmonary
complications such as aspiration, atelectasis, hypoxemia, and respiratory failure. Therefore,
background information about neuromuscular blocking agents and neuromuscular monitoring is
necessary in order to fully understand and compare the effects of neostigmine and sugammadex
in reversal of neuromuscular blockade.
Depolarizing Neuromuscular Blocking Agent
The only depolarizing neuromuscular blocking agent that is currently used is
succinylcholine. It functions by attaching itself to the acetylcholine receptor, resulting in a
prolonged depolarization, which inactivates the receptor (Butterworth, Mackey, & Wasnick
2018). Succinylcholine is typically not used in the pediatric population, except in emergency or
difficult airway situations. This is because undiagnosed myopathies may be present in children,
which could lead to complications if succinylcholine is administered. The most common
complications include rhabdomyolysis, hyperkalemia, and profound bradycardia, which can lead
to cardiac arrest (Butterworth et al., 2018). Because of this, the U.S. Food and Drug
Administration (FDA) issued a black box warning for succinylcholine use in the pediatric
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population. If succinylcholine must be administered to a pediatric patient, it is usually
administered intramuscularly along with atropine. Atropine, an anticholinergic agent, will
prevent the profound bradycardia that can occur with succinylcholine administration in children.
Because of the potential for these complications to occur, nondepolarizing neuromuscular
blocking agents are preferred in the pediatric population.
Nondepolarizing Neuromuscular Blocking Agents
Nondepolarizing neuromuscular blocking agents work by attaching to acetylcholine
receptors at the neuromuscular junction. However, they do not cause a conformational change to
the receptor, such as succinylcholine, and do not produce an action potential. Instead, they only
block acetylcholine from binding to the receptor.
Nondepolarizing neuromuscular blocking agents can be divided into two different
classifications: aminosteroidal and benzylisoquinoline. Aminosteroidal neuromuscular blocking
agents, which include rocuronium and vecuronium, are the most commonly used neuromuscular
blocking agents. Rocuronium and vecuronium have a steroidal structure with an attached amino
group, which is important, as the structure is what allows sugammadex to bind to it.
Benzylisoquinoline neuromuscular blocking agents have a different structure which, does not
bind to sugammadex, and therefore are not included in the current research. Unlike vecuronium,
rocuronium undergoes minimal metabolism and produces no active metabolites. Therefore, the
most commonly used neuromuscular agent to induce paralysis in the pediatric population is
rocuronium (Tarquinio et al., 2015).
Neuromuscular Monitoring
The level of neuromuscular blockade should be monitored whenever a neuromuscular
blocking agent is administered, especially in pediatric patients. Monitoring is essential to
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measure the level of neuromuscular blockade and to determine how much agent is required to
reverse neuromuscular blockade. The effects of all neuromuscular agents, both depolarizing and
nondepolarizing, can be measured. Traditionally, recovery was evaluated by the patient lifting
their head for five seconds, squeezing the anesthesia providers’ hands, and breathing without
difficulty (Yang et al., 2014). Most anesthesia providers now monitor neuromuscular blockade
using peripheral nerve stimulators to measure train of four.
Train of four. The concept of train of four monitoring using peripheral nerve stimulators
is important as it is used in almost all research involving the administration of paralytics and
reversal of neuromuscular blockade. The preferred location for train of four monitoring in
pediatric patients is on the ulnar nerve, which contracts the adductor pollicis muscle (Klucka et
al., 2019). Stimuli are applied to the ulnar nerve, and the more neuromuscular blocking agent
bound to the neuromuscular endplate, the fewer responses to the stimuli. For example, a train of
four of zero, or no twitches, indicates that there is > 95% neuromuscular blockade. A train a four
of 4 (T4), or four twitches, indicates that there is < 75% neuromuscular blockade (Hunter, 2017).
The ratio between the strength of the response of T1 and T4 is known as the train of four ratio.
The higher the train of four ratio, the more neuromuscular blockade reversal has occurred.
Until recently, a train of four ratio of 0.7 was considered to be a sign of sufficient neuromuscular
recovery (Tajaate et al., 2018). This was based on the fact that tidal volume and vital capacity,
two important respiratory parameters, begin to recover at a train of four ratio of 0.7 (FuchsBuder et al., 2016). However, new research shows that a train of four ratio of ≥ 0.9 is now
considered to be a sign of sufficient neuromuscular recovery (Plummer-Roberts et al., 2016).
Even though a train of four ratio of 0.9 is now considered to be the standard cutoff for sufficient
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neuromuscular recovery, it is important to note that residual neuromuscular blockade may persist
in some patients at that level.
Residual Neuromuscular Blockade
Residual postoperative neuromuscular blockade occurs when the patient experiences
residual muscular weakness related to the incomplete reversal of neuromuscular blocking agents.
Residual blockade can occur whether or not the patient has been given a reversal agent. Research
by Brull et al. (2018) shows that residual neuromuscular blockade occurs in 20-60% of patients
receiving a nondepolarizing neuromuscular agent, such as rocuronium. According to Yang et al.
(2014), residual neuromuscular block occurs in 2-64% of patients regardless of the type of
neuromuscular blocking agent. Fortier et al. (2015), investigated the incidence of residual block
in patients that had received rocuronium or vecuronium and had been given a reversal agent. The
study showed that the incidence of residual block, even after having received a reversal agent,
was 56%. Another study by Brueckmann et al. (2015), found that 43% of patients arriving in the
post anesthesia care unit had residual blockade with a train of four ratio < 0.9 and 11% of
patients were found to have a train of four ratio < 0.7. A survey conducted in the United States
and Europe amongst anesthesia providers showed that 77% of those surveyed felt that residual
neuromuscular blockade was a major public health issue (Naguib et al., 2010).
Residual neuromuscular blockade after administration of nondepolarizing neuromuscular
blockers has been found to cause postoperative pulmonary complications in all populations.
Residual paralysis postoperatively leads to impaired function of the upper airway with increased
pharyngeal dysfunction and swallowing difficulties, leading to increased risk for aspiration
(Tajaate et al., 2018). Residual paralysis can lead to respiratory insufficiency due to decreased
muscle strength, as well as increasing the risk for upper airway obstruction during inhalation and
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increasing the risk for silent aspiration (Fuchs-Buder et al., 2016; Hristovska et al., 2017).
Patients in the post anesthesia care unit with respiratory complications were found to have higher
incidences of residual neuromuscular blockade than patients without complications (FuchsBuder et al., 2016). Other complications resulting from residual neuromuscular blockade include
hypoxemia, hypercarbia, and atelectasis (Wiatrowski et al., 2018). Failure to ensure the reversal
of neuromuscular blockade and to monitor for residual paralysis can lead to respiratory failure,
prolonged intubation, and admission to the intensive care unit (ICU) (Murphy, 2018). Some
pediatric patients are at even greater risk due to their immature respiratory musculature,
diminished functional residual capacity, and reduced surface area for gas exchange. Other factors
that put young pediatric patients at greater risk for postoperative respiratory failure include
collapsible airways, loss of protective reflexes, and poor lung compliance (Trachsel et al., 2016).
Sugammadex
Sugammadex, which was developed by Merck Pharmaceuticals under the trade name
Bridion, was approved for use in adults in the United States by the Food and Drug
Administration (FDA) on December 2015, after eight years of clinical trials (Murphy, 2016).
Sugammadex has been approved for use in adults and children aged 2-17 years in Europe since
2008 and in Japan since 2010. In the United States, the FDA has not approved sugammadex for
use in children due to concerns regarding hypersensitivity and allergic reactions (Young et al.,
2016). A great deal of research has been performed in the United States comparing neostigmine
and sugammadex in adults; however, the same research on the pediatric population of the United
States is scarce.
Sugammadex is a selective relaxant binding agent with a unique approach to reversing
nondepolarizing aminosteroidal neuromuscular blocking agents. Its structure consists of a
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modified gamma cyclodextrin ring designed to encircle aminosteroidal neuromuscular blocking
agents, such as rocuronium or vecuronium (Nag et al., 2013). Sugammadex is able to bind to
rocuronium and vecuronium at a ratio of 1:1 (Cada et al., 2016). The mechanism of action of
sugammadex is unique in that it is a direct method of removing nondepolarizing neuromuscular
blocking agents, as opposed to neostigmine, which uses an indirect method.
Sugammadex does not bind to plasma protein or red blood cells and does not require
administration of anticholinergics, as it has no effect on acetylcholine, acetylcholinesterase, or
acetylcholine receptors (Sugammadex, 2019). Sugammadex and the sugammadex-rocuronium
complex are not metabolized by the body and are excreted unchanged by the kidneys (Nag et al.,
2013). The recommended dosage of sugammadex for adults depends upon the level of
neuromuscular blockade. If two or more twitches are present (≥ T2), the dose is 2 mg/kg. If there
is deep neuromuscular blockade, with no twitches, but a post-tetanic count of 1-2, then the
reversal dose is 4 mg/kg. If there is deep neuromuscular blockade, with no twitches, and a posttetanic count of zero, then the reversal dose is 16 mg/kg (Merck Sharp & Dohme Corp., 2018).
16mg/kg is considered the maximum dose of sugammadex and is typically given in a ‘cannot
intubate, cannot ventilate’ situation (Hunter, 2017).
Neostigmine and Glycopyrrolate
Neostigmine functions by binding to acetylcholinesterase, which allow acetylcholine to
build up at the neuromuscular junction. This allows acetylcholine to compete with
nondepolarizing neuromuscular blockers at acetylcholine receptors. Although
acetylcholinesterase inhibitors seem to be ideal for reversing nondepolarizing neuromuscular
blockade, there are some issues associated with them. The indirect method in which they reverse
neuromuscular blockade means that reversal can be unpredictable and recurarization is possible
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(Hristovska et al., 2017). Recurarization occurs when the reversal medication wears off and there
is still sufficient neuromuscular blocking agent available in the body to cause residual
neuromuscular blockade. Another problem with acetylcholinesterase inhibitors is the autonomic
parasympathetic responses that occur after administration. Neostigmine is associated with
bradycardia, bronchospasm, dysrhythmias, miosis, and other muscarinic side effects
(Neostigmine, 2019). These agents have also been implicated in causing postoperative nausea
and vomiting (Koyuncu, 2015; Paech, 2018).
Anticholinergic agents, such as glycopyrrolate, are administered with
acetylcholinesterase inhibitors to blunt the autonomic parasympathetic responses that occur.
Glycopyrrolate is generally administered with neostigmine as they have a similar onset and
duration of action. However, glycopyrrolate can cause its own side effects such as tachycardia
and confusion.
Limitations of neostigmine. Although neostigmine has been used to reverse
neuromuscular blockade for more than 50 years, it does have its disadvantages. In order for
neostigmine to adequately reverse neuromuscular blockade, it is currently recommended there be
at least 2 twitches (≥ T2) present using train of four monitoring. Research conducted by Tajaate
et al. (2018), shows that neostigmine was not effective in maintaining reversal of neuromuscular
blockade in individuals with less than 2 twitches using train of four monitoring. If neostigmine is
given with fewer than two twitches (≤ T2), there is an increased chance of recurarization
occurring during the postoperative period. Recurarization is the return of neuromuscular
blockade after some period of recovery. Thus, administration of neostigmine for reversal of deep
neuromuscular blockade is not recommended.
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Furthermore, due to the pharmacokinetics of neostigmine, reversal to a train of four ratio
of > 0.9 can take more than 10 minutes. Although the onset for neostigmine is 1 minute, it does
not reach its peak effect until about 9 minutes. This constraint of neostigmine may be explained
as a ceiling effect. Because neostigmine works indirectly at acetylcholine receptors, there is a
point where acetylcholinesterase inhibition reaches 100%. However, even with complete
acetylcholinesterase inhibition, acetylcholine levels have not reached a point where they can
overcome the competitive inhibition of nondepolarizing neuromuscular blockers, such as
rocuronium (Tajaate et al., 2018). Thus, giving more neostigmine would not have any further
effect at reversing neuromuscular blockade. This plateau is termed the ceiling effect and is why
there is a total maximum dose of 0.7 mg/kg or 5mg, whichever is less, during reversal
(Hristovska et al., 2017). Several studies involving administration of neostigmine for reversal of
neuromuscular blockade revealed it took more than 15 minutes for a train of four ratio > 0.9 after
administration of neostigmine (Hristovska et al., 2017; Ozgun et al., 2014).
Neostigmine is associated with several muscarinic side effects, which is why it is
administered with an anticholinergic such as glycopyrrolate. Even with administration of an
anticholinergic, some muscarinic effects can occur. The most common side effects of
neostigmine administration are bradycardia, bronchoconstriction, miosis, laxation, and nausea
and vomiting. Bradycardia, bronchoconstriction, and nausea/vomiting are even more of a
concern in the pediatric population as any of them can lead to hypoxemia and respiratory
complications.
Comparison of Neostigmine and Sugammadex
As previously mentioned, neostigmine requires that at least 2 twitches (≥ T2) be present
using train of four monitoring before administration. When neostigmine is given with fewer than
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two twitches (≤ T2), there is increased incidence of recurarization. Sugammadex does not require
any twitches to be present using train of four monitoring, and it can even be used when there is a
deep neuromuscular block with no post-tetanic twitches. Furthermore, there is less incidence of
residual neuromuscular blockade with administration of sugammadex than with neostigmine. A
study by Brueckmann et al. (2015) on adults showed that 0% of the patients reversed with
sugammadex had any residual neuromuscular blockade, while 43% of the patients reversed with
neostigmine had residual blockade.
Sugammadex has also been found to have less adverse effects than neostigmine.
Bradycardia, which was found to be the most common side effect associated with neostigmine
administration, was present in 14% of patients. However, only 2% of patients receiving
sugammadex experienced any bradycardia (Koyuncu et al., 2015). Information provided by
Merck Pharmaceuticals, the manufacturer of sugammadex, suggests that bradycardia is possible,
however, studies have shown that the incidence of bradycardia is lower in groups receiving
sugammadex versus neostigmine (Gaver et al., 2017; Hristovska et al., 2017; Hunter, 2017).
Issues concerning administration of sugammadex and QT prolongation were found to be not
clinically relevant (Honing et al., 2019).
Postoperative pulmonary complications are more common in patients receiving
neostigmine versus sugammadex. A study by Ledowski et al. (2014) showed that reversal with
sugammadex, or no reversal, had less postoperative pulmonary complications than administering
neostigmine for reversal. This implies that sugammadex reduces the risk of postoperative
pulmonary outcomes by more efficiently reversing residual neuromuscular blockade and
presenting fewer adverse effects. It also implies that reversal with neostigmine was found to not
be beneficial and actually had a harmful association with postoperative complications.
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Postoperative nausea and vomiting are among the most common postoperative
complications after anesthesia. Research shows that there is a decreased incidence in
postoperative nausea and vomiting with administration of sugammadex versus neostigmine
(Gonheim et al., 2018; Koyuncu et al., 2015). The study by Koyuncu et al. (2015), demonstrated
that administration of sugammadex lowered the incidence of nausea and vomiting
postoperatively, while administration of neostigmine increased the incidence of nausea and
vomiting postoperatively. It is suggested that this could be due to the faster recovery from
neuromuscular blockade using sugammadex, but it may also be due to the muscarinic effects of
neostigmine administration.
Sugammadex and the Pediatric Population
There have been many studies that show the efficacy and safety of sugammadex in
reversing neuromuscular blockade in the adult population without adverse effects. However, the
pharmacokinetic and pharmacodynamic profiles of medications differ between adult patients and
pediatric patients. For example, the extracellular space is greater in children than adults and this,
at times, requires higher doses of medications. Furthermore, in neonates, the neuromuscular
junction is not fully developed and the affinity of receptors to rocuronium is reduced. Thus,
larger doses of rocuronium are required, which can cause difficulties during emergence (Turk et
al., 2019). Anesthesia-related complications during the perioperative period have been found to
be a significant cause of childhood morbidity (Mir-Ghassemi et al., 2015). Therefore, the use of
sugammadex is investigated to determine if it is safe in the pediatric population.
Although there is little research in the United States regarding administration of
sugammadex in the pediatric population, there are several studies from around the world that
show it is safe in the reversal of neuromuscular blockade with minimal side effects. A systematic
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review by Honing et al. (2019) researched the safety of sugammadex in different age groups. The
review determined that sugammadex is equally as safe and effective in pediatric patients as in
adult patient after studying adverse effects between all groups. Adverse effects associated with
sugammadex use in adults, including anaphylaxis, hypersensitivity, QT prolongation, and
anticoagulation, were investigated and were found not to be clinically significant.
One concern of the FDA regarding administration of sugammadex to children involves
issues with anaphylaxis. Several studies have shown that there is no clinically significant
relationship between administration of sugammadex and anaphylaxis or hypersensitivity
reactions. Sari et al. (2013) conducted a study to determine if there were any side effects
associated with administration of sugammadex in children. The study included infants, children,
and adolescents receiving rocuronium for neuromuscular blockade during surgery. The results
show that there was no hypersensitivity, bradycardia, or bronchospasm related to the
administration of sugammadex. Another study conducted by Tadakoro et al. (2018) searched for
an association between the administration of sugammadex in children and anaphylaxis. The
study found that 0.056% of patients had a ‘probable’ anaphylactic reaction associated with
administration of sugammadex. Therefore, no significant association was found between the
administration of sugammadex and anaphylaxis in pediatric patients (Tadakoro et al., 2018).
As previously mentioned, bradycardia in one study was reported to occur in about 2% of
the adult population. Bradycardia in children is associated with sudden death and is considered
an early warning sign. However, studies show that the incidence of bradycardia in children is
low, and it is more common in children receiving neostigmine than sugammadex (Gaver et al.,
2017; Honing et al., 2019; Liu et al, 2017). A study by Simonini et al. (2019) noted that the one
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complication that could be related to sugammadex was increased bradycardia as the dose of
sugammadex increased.
Sugammadex has been shown to quickly and efficaciously reverse rocuronium induced
neuromuscular blockade in the pediatric population. Reversal occurs when sugammadex binds
rocuronium to form a sugammadex-rocuronium complex, thus removing it from the
neuromuscular endplate. Several studies show that pediatric patients were able to reach a train of
four ratio > 0.9 significantly faster than and more predictably than using neostigmine (Alonso et
al., 2014; Ammar et al., 2017; Gaver et al., 2017; Ghoneim et al., 2018; Liu et al., 2017; Ozgun
et al., 2014; Plaud et al., 2009; Young et al., 2016). Furthermore, other recovery parameters, such
as muscle strength, head elevation, and return of consciousness appeared faster in the group
receiving sugammadex (Ozgun et al., 2014).
Plaud et al. (2009) compared reversal of neuromuscular blockade by rocuronium in
infants, children, adolescents, and adults. In the study, he administered a placebo or 2mg/kg of
sugammadex to patients with two twitches (T2) using train of four monitoring. The results
showed that the group given the placebo took 21.0, 19.0, 23.4, and 28.5 minutes, respectively, to
reach a train of four ratio of 0.9. However, the group receiving sugammadex took 0.6, 1.2, 1.1,
and 1.2 minutes, respectively, to reach a train of four ratio of 0.9 (Plaud et al., 2009). This is
significantly faster than the group receiving the placebo. No recurarization was observed and,
although some adverse events were observed, they were not found to be linked to sugammadex
administration.
Although there is little research involving sugammadex and neonates, the studies that
have been performed show that sugammadex is just as safe, fast, and predictable in that
population (Alonso et al., 2014; Turk et al., 2019). Alonso et al. (2014) conducted a study on the
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effect of sugammadex on neonates to determine its efficacy and safety. The results show that,
although the neonatal patients showed profound neuromuscular block after administration of
rocuronium, a dose of 4 mg/kg of sugammadex was sufficient to reach a train of four ratio > 0.9
within minutes (Alonso et al., 2014). Furthermore, there were no observed adverse events,
recurarization, or change in vital signs. Turk et al. (2019) conducted a retrospective study on the
effects of sugammadex on neonates who were administered rocuronium. The mean age of the
patients studied was 10.3 days, the mean weight of the patients was 3.0 kg, and the mean dose of
sugammadex administered was 3.6 mg/kg. The results show that the time it took to reach a train
of four ratio > 0.9 was 88 seconds (Turk et al., 2019). There were no signs of recurarization, and
no adverse effects were noted.
Dosing of sugammadex in the pediatric population is unclear as only recommendations
are available. In countries where sugammadex is approved in children, the recommended dose
for children aged 2-17 years is 2 mg/kg. No recommendations are currently available for children
aged less than 2 years. This is due to a lack of data related to the administration of sugammadex
in infants and neonates. Matsui et al. (2019) studied the effects of sugammadex in reversing
rocuronium induced neuromuscular block in infants and children. The study consisted of
administering different doses of sugammadex to determine the appropriate dosage in infants and
children. Sugammadex was administered when the post-tetanic count reached 1-2, with one
group receiving 1 mg/kg, the second group receiving 2 mg/kg, and the third group receiving 4
mg/kg. The results showed that 1 mg/kg of sugammadex was not sufficient to reach a train of
four ratio > 0.9 (Matsui et al., 2019). No difference was seen in the time necessary to reach a
train of four ratio > 0.9 between the groups receiving 2 mg/kg and 4 mg/kg. This is significant,
as it had been previously thought that a dose of 4 mg/kg was required to reverse deep
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neuromuscular blockade. The authors noted that the faster recovery in infants and children versus
adults could be related to the larger relative cardiac output present in infants and children
(Matsui et al., 2019).
As previously mentioned, sugammadex can be administered for reversal of deep
neuromuscular blockade. Therefore, it can be given even when there are no twitches and a posttetanic count of zero. Studies have shown that sugammadex is able to reverse deep
neuromuscular blockade in the pediatric population with no adverse effects (Ammar et al., 2017;
Franz et al., 2018). Ammar et al. (2017) compared neostigmine and sugammadex in reversing
rocuronium induced neuromuscular blockade in children. In the study, one group of children
received 0.35 mg/kg neostigmine along with 0.02 mg/kg of atropine, while the other group
received 4 mg/kg of sugammadex. The group receiving neostigmine/atropine had to wait until
two twitches (T2) were present with train of four monitoring before reversal. The group
receiving sugammadex received the dose once they had a post-tetanic count of 1-2, meaning that
they had zero twitches with train of four monitoring. The results showed that reversal time with
the sugammadex group was significantly faster than with the neostigmine/atropine group
(Ammar et al., 2017). The neostigmine/atropine group reached a train of four ratio > 0.9 at 12.6
minutes versus the sugammadex group which reached a train of four ratio of > 0.9, from a deeper
block, at 2.5 minutes. Notably, some individuals in the neostigmine/atropine group required an
additional dose due to recurarization. Ammar et al. (2017) went on to mention that pediatric
patients with cardiovascular or respiratory issues should receive sugammadex instead of
neostigmine/atropine because they may not tolerate the adverse effects associated with it.
Franz et al. (2018) conducted a study to compare the effects of sugammadex and
neostigmine for reversal of rocuronium or vecuronium induced neuromuscular block in pediatric
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patients under 2 years of age. The study found that sugammadex is able to be given sooner than
neostigmine because it can be given if the patient has a deep neuromuscular block, while
neostigmine requires the presence of at least two twitches (T2) using train of four monitoring.
Sugammadex has also been found to be associated with less incidence and lower severity
of emergence agitation. Kim et al. (2018) conducted a study of children aged 1 to 13 years who
received sugammadex after receiving rocuronium for strabismus surgery. The data shows that
the group that received sugammadex had lower incidences of emergence agitation and lower
severity of emergence agitation than the group receiving pyridostigmine (Kim et al., 2018).
Limitations of Sugammadex
Although the development of sugammadex is a breakthrough for the reversal of
neuromuscular blockade, it does have some limitations. As previously mentioned, sugammadex
encapsulates aminosteroidal nondepolarizing neuromuscular blocking agents. Therefore, it will
not work on depolarizing neuromuscular blockers or benzylisoquinoline nondepolarizing
neuromuscular blocking agents. It has also been found that sugammadex will also encapsulate
other steroidal compounds, such as estrogen compounds, flucloxacillin, and some antifungal
medications (Ledowski et al., 2014). Administration of an aminosteroidal nondepolarizing
neuromuscular blocking agent after administration of sugammadex will not produce a
neuromuscular block, as sugammadex will continue to function for hours after administration
(Sugammadex, 2019). A waiting time of 24 hours is recommended before re-administration of
rocuronium or vecuronium. Benzylisoquinoline nondepolarizing neuromuscular blocking agents
may be used instead for neuromuscular blockade. Sugammadex is an expensive medication and
may not be available for use in all hospital settings. Therefore, alternative neuromuscular
blockade reversal agents must be available. Sugammadex is not recommended for individuals
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with severe renal impairment or on dialysis as the sugammadex-rocuronium complex is excreted
unchanged via the kidneys.
Sugammadex has been associated with hypersensitivity reactions and anaphylactic shock.
Tadakoro et al. (2018) suggest that the gamma cyclodextrin structure of sugammadex may be
responsible for the reactions. These structures are found in foods, dyes, and fat soluble vitamins
and supplements. Another possibility is that the cyclodextrin structure may somehow alter the
body’s immune response. Takazawa et al. (2016) suspect the sugammadex-rocuronium complex
may be to blame. The most frequent symptoms associated with sugammadex related anaphylaxis
are hypotension, tachycardia, and skin rash (Iwasaki et al., 2017). Bradycardia and a prolonged
QT interval have occurred with some individuals soon after administration of sugammadex
(Sugammadex, 2019). If bradycardia is observed and is symptomatic, it should be treated
immediately with anticholinergics. Rahe-Meyer et al. (2014) suggest that prolongation of the
activated prothrombin time, prothrombin time, and international normalized ratio (INR) can
occur after administration with sugammadex.
Discussion
Sugammadex and neostigmine/glycopyrrolate are the most common agents used for
reversal of neuromuscular blockade induced by aminosteroidal nondepolarizing neuromuscular
blocking agents in adults. However, sugammadex has not been approved by the FDA for use in
the pediatric population in the United States. The other option for reversal in children would be
administration of neostigmine and glycopyrrolate, although this combination can cause a myriad
of adverse effects. Neostigmine is associated with more postoperative pulmonary complications
than sugammadex, and one study suggested that it is directly associated with prolonged post
anesthesia care unit stay. Furthermore, neostigmine and glycopyrrolate cannot be used to reverse
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deep neuromuscular blockade. Several studies have shown that sugammadex reversed
neuromuscular blockade significantly faster than neostigmine with less side effects, and it can
also be used to reverse deep neuromuscular blockade. Sugammadex is associated with decreased
anesthesia time, decreased recovery time, and decreased length of hospital stay, as well as less
postoperative complications, such as nausea, emergence agitation, and recurarization. It has been
suggested that pediatric patients with cardiovascular or respiratory issues should receive
sugammadex instead of neostigmine/atropine because they may not tolerate the adverse effects
associated with administration. Furthermore, sugammadex is so unique in its function it has been
suggested that it should be included in enhanced recovery after surgery (ERAS) protocols
(Young et al., 2016). Sugammadex use in pediatric populations has been shown to be as equally
safe and effective as in adult populations with minimal adverse effects.
Off-label use of medications is common in pediatrics. It can be considered acceptable if
the benefits outweigh the risks, especially in a life-threatening situation. Fortunately, European
guidelines exist for sugammadex use in children and they can be utilized, if such a situation were
to arise. One such situation would be a ‘cannot intubate, cannot ventilate’ situation. If
sugammadex were to become a standard of care in the United States for pediatric patients, the
patient could receive a larger dose of rocuronium in an emergent situation instead of having to
administer succinylcholine, as the resulting deep neuromuscular block could easily be reversed
without adverse effects.
There are a few limitations in the research that require discussion. There is not much
research that has been done on the subject in the United States, as it is difficult to obtain
permission to perform research on children. Furthermore, the use of sugammadex in children has
not been approved by the FDA. The FDA’s concern is more than likely due to the rare
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hypersensitivity and anaphylactic reactions that have occurred, along with episodes of
bradycardia that have been reported in adults. Merck Sharp & Dohme Corp. (2018) did conduct
several juvenile animal studies during preclinical trials. One of the studies compared bone
deposition of sugammadex between juvenile and adult rats. Sugammadex deposition in juvenile
rats was found to be 13% while deposition in adults was only 3% following a single IV dose of
30mg/kg. Another study dosed 7 day old rats daily with increasing doses of sugammadex for 28
days. The study showed that ulna and femur bone lengths were found to be 3% shorter in groups
receiving 120 and 500 mg/kg daily (Merck Sharp & Dohme Corp., 2018). Tooth and enamel
malformation, as well as discoloration, was also observed.
Most of the studies that have been published are European studies, and most of those
have relatively small sample sizes. Several of the studies are retrospective observational studies.
Furthermore, the studies are limited by the accuracy of data collection and the level of blinding
and randomization. Lastly, some of the studies have an unclear risk of bias.
Conclusion
Sugammadex, a selective relaxant binding agent, employs a novel method of inactivating
nondepolarizing neuromuscular blocking agents, which rapidly and efficiently reverses
neuromuscular blockade in the pediatric population. Administration of sugammadex is safe at all
ages, works significantly faster than neostigmine in reversing neuromuscular blockade, and has
fewer adverse effects than neostigmine. Furthermore, it has the ability to reverse from a deep
neuromuscular blockade, which neostigmine cannot do. It has been found to be equally as safe
and effective in the pediatric population as in the adult population. Nonetheless, more research
should be performed on the subject, particularly long-term studies, to gather more data to ensure
its effectiveness and safety in the pediatric population.
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